Frank Carr
Merck & Co. (NYSE:MRK), the pharmaceutical giant behind blockbuster cancer drug Keytruda and a broad portfolio of vaccines and medicines, is facing fresh scrutiny in Washington after a bipartisan group of lawmakers opened national security investigations into clinical trials the company has run in China. Shares dipped 0.68% on the news cycle surrounding the inquiry, closing at 128.5 dollars.
At a Glance
- Price: 128.5 USD, down 0.68% on the day
- 52 week range: 107.9 to 130.29
- Market cap: 317.77 billion dollars
- P/E ratio: 35.99, EPS derived yield reflected in valuation
- Dividend yield: 2.65%, RSI at 68.01
| Price | 128.5 USD |
|---|---|
| Day change | -0.88 (-0.68%) |
| 52-week range | 107.9 – 130.29 |
| Market cap | $317.77B |
| P/E ratio | 35.99 |
| EPS (ttm) | 3.57 |
| Dividend yield | 2.65% |
| RSI (14) | 68.01 |
| Volume | 11,837,218 |
Lawmakers Target Trial Sites in Xinjiang
Representative John Moolenaar of Michigan, who chairs the House committee focused on competition with China, sent letters dated Monday to Merck and fellow drugmaker AbbVie. The letters, addressed to Merck chief executive Robert Davis and AbbVie chief executive Robert Michael, ask both companies to hand over details by July 17 covering due diligence practices, data protection protocols and other standards applied at trial sites in China, with particular attention paid to facilities in the Xinjiang region and at military hospitals.
The committee's letters describe Xinjiang as the center of what they call a campaign of genocide against Uyghurs and other ethnic and religious minorities, and they cite documented lapses by Chinese researchers in obtaining informed consent from trial participants. Lawmakers also referenced the Uyghur Forced Labor Prevention Act of 2021, noting that while the law does not directly regulate clinical trials, it sets a benchmark for ethical conduct that companies should be following when operating in the region.
Merck responded by stating that patient safety and ethical integrity remain central to its clinical research program and that it adheres to global guidelines wherever it operates. AbbVie declined to comment on the matter. A spokesperson for China's embassy in Washington pushed back sharply, saying there is nothing credible behind the committee's actions and accusing lawmakers of politicizing trade and technology disputes.
Why China Has Become a Trial Hub
The letters argue that a mix of regulatory changes, government subsidies and what they term questionable ethical standards has turned China into the fastest and cheapest place in the world to conduct early stage human drug trials. That shift shows up in the numbers: by 2024, the United States share of global early drug development programs had fallen to roughly 37% from 48% in 2015, while China's share climbed to more than 32% from just 8% over the same period, based on findings cited in the lawmakers' letters.
This isn't an isolated flashpoint. A December report from the National Security Commission on Emerging Biotechnology warned that China has built a vertically integrated biotech ecosystem positioned to challenge American dominance in the sector. The Merck and AbbVie inquiries fit into that broader pattern of congressional unease about how deeply intertwined U.S. drug development has become with Chinese trial infrastructure.
Notably, the letters stop short of alleging wrongdoing. They state plainly that there is no evidence either company engaged in illegal conduct, but argue that running trials in China exposes American drugmakers to ethical and security risks worth examining.
What the Numbers Say
Merck trades at a P/E ratio of 35.99, a multiple that sits well above the pharmaceutical sector's historical norms and suggests investors are pricing in continued growth from Keytruda and the company's pipeline rather than valuing it as a mature, slow growth drugmaker. The stock's current price of 128.5 dollars sits near the top of its 52 week range of 107.9 to 130.29, reflecting a steady climb rather than a sharp break in either direction.
The RSI reading of 68.01 puts Merck close to overbought territory without quite crossing into it, a sign that recent buying momentum has been strong but may be due for a pause. Income focused investors, meanwhile, continue to collect a 2.65% dividend yield, a figure that has helped keep the stock attractive even as its price has risen toward the upper end of its yearly range.
The bull case rests on Merck's diversified drug portfolio and its scale, with a market cap of 317.77 billion dollars giving it the financial cushion to absorb regulatory noise like the current congressional inquiry without operational disruption. The bear case centers on valuation risk: a P/E near 36 leaves little room for error, and any escalation in the China trial investigation, whether through new restrictions on data sharing or reputational fallout, could weigh on sentiment even without evidence of wrongdoing.
Frequently Asked Questions
What exactly are lawmakers investigating?
They are examining whether Merck and AbbVie followed proper due diligence, data protection and ethical standards in clinical trials conducted in China, particularly in Xinjiang and at military hospitals.
Has either company been accused of wrongdoing?
No. The lawmakers' letters explicitly state there is no evidence of illegal activity by either company, though they argue the trials carry ethical and security risks.
Why has China become a major hub for drug trials?
Lower costs, faster regulatory processes and government subsidies have made China an increasingly popular location for early stage drug testing, with its share of global trials rising sharply since 2015.
How has Merck stock reacted to the news?
Shares fell 0.68% to 128.5 dollars, still near the upper end of the stock's 52 week range of 107.9 to 130.29.
Watching How Washington's Scrutiny Unfolds
Merck and AbbVie now face a July 17 deadline to respond to the committee's requests, and how thoroughly they comply could shape the next phase of this story. For now, the inquiry adds a layer of political risk to a stock that markets have otherwise treated favorably, and investors will be watching whether the scrutiny expands beyond these two companies to other drugmakers with a footprint in China.
Sarah Ross